Amitriptyline/Gabapentin

Phase 3Small molecule

JJocelyn Fitzgerald

Amitriptyline/Gabapentin is one of 7 small molecule programs targeting Chronic Pelvic Pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Pelvic PainActive, not recruiting

Chronic Pelvic PainPhase 3

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Chronic Pelvic Pain

#DrugCompanyPhaseTrials

Activella

Eli Lilly

Phase 3

1 2

Amitriptyline/Gabapentin

JJocelyn Fitzgerald

Phase 3

1 3

Psilocybin

COMPASS Pathways

Phase 1

1 4

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 5

Pharmacotherapy

UUniversity of Pittsburgh

Preclinical

1 6

Botulinum Neurotoxin

TThe University of Texas Health Science Center, Houston

Phase 1

2 7

Onabotulinumtoxin a

Lundbeck

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Pelvic Pain1 trial

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

Active, not recruiting·JJocelyn Fitzgerald·Phase 3·NCT05658874·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amitriptyline/Gabapentin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amitriptyline/Gabapentin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amitriptyline/Gabapentin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jocelyn Fitzgerald company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJocelyn Fitzgerald

Amitriptyline/Gabapentin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Pelvic Pain1 trial

References

Drug Info

Quick Facts

Related News